<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="al48 assessed the safety and efficacy of PD-1 inhibition by" exact="pembrolizumab" post="with different predisposing conditions (n=8). In this small cohort,"/>
 <result pre="Nevertheless, it seems that early and short-time use of low-dose" exact="methylprednisolone" post="may be one feasible approach in SARS-COV-2-related pneumonitis and"/>
 <result pre="syndrome.83 Hence, possible ICI-induced irAEs could be safely managed with" exact="methylprednisolone" post="in the setting of COVID-19. Based on the observation"/>
 <result pre="to compare the efficacy of the combined administration of a" exact="chloroquine" post="analog, nivolumab, and tocilizumab versus standard of care in"/>
 <result pre="randomized into two different cohorts: (1) asymptomatic or mild symptoms:" exact="chloroquine" post="analog versus nivolumab versus standard of care (1:1:1); (2)"/>
 <result pre="versus nivolumab versus standard of care (1:1:1); (2) moderate/severe symptoms:" exact="chloroquine" post="analog versus tocilizumab versus standard of care (1:1:1). It"/>
 <result pre="of care (1:1:1). It has to be stressed, however, that" exact="hydroxychloroquine" post="use has been reported to be ineffective or even"/>
</results>
